|
1
|
Palumbo A and Anderson K: Multiple
myeloma. N Engl J Med. 364:1046–1060. 2011.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Bhutani M, Foureau DM, Atrash S, Voorhees
PM and Usmani SZ: Extramedullary multiple myeloma. Leukemia.
34:1–20. 2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Sevcikova S, Minarik J, Stork M, Jelinek
T, Pour L and Hajek R: Extramedullary disease in multiple
myeloma-controversies and future directions. Blood Rev. 36:32–39.
2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Lu J, Lu J, Chen W, Huo Y, Huang X and Hou
J: Chinese Medical Doctor Association Hematology Branch. Clinical
features and treatment outcome in newly diagnosed Chinese patients
with multiple myeloma: Results of a multicenter analysis. Blood
Cancer J. 4(e239)2014.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Rajkumar SV, Dimopoulos MA, Palumbo A,
Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E,
Richardson P, et al: International myeloma working group updated
criteria for the diagnosis of multiple myeloma. Lancet Oncol.
15:e538–e548. 2014.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Palumbo A, Avet-Loiseau H, Oliva S,
Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S,
Lahuerta JJ, Facon T, et al: Revised International staging system
for multiple myeloma: A report from International myeloma working
group. J Clin Oncol. 33:2863–2869. 2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Paludo J, Painuly U, Kumar S, Gonsalves
WI, Rajkumar V, Buadi F, Lacy MQ, Dispenzieri A, Kyle RA, Mauermann
ML, et al: Myelomatous involvement of the central nervous system.
Clin Lymphoma Myeloma Leuk. 16:644–654. 2016.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Fassas AB, Muwalla F, Berryman T,
Benramdane R, Joseph L, Anaissie E, Sethi R, Desikan R, Siegel D,
Badros A, et al: Myeloma of the central nervous system: Association
with high-risk chromosomal abnormalities, plasmablastic morphology
and extramedullary manifestations. Br J Haetomal. 117:103–108.
2002.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Fassas AB, Ward S, Muwalla F, Van Hemert
R, Schluterman K, Harik S and Tricot G: Myeloma of the central
nervous system: Strong association with unfavorable chromosomal
abnormalities and other high-risk disease features. Leuk Lymphoma.
45:291–300. 2004.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Sonneveld P, Avet-Loiseau H, Lonial S,
Usmani S, Siegel D, Anderson KC, Chng WJ, Moreau P, Attal M, Kyle
RA, et al: Treatment of multiple myeloma with high-risk
cytogenetics: A consensus of the International myeloma working
group. Blood. 127:2955–2962. 2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Raza S, Safyan RA and Lentzsch S:
Immunomodulatory drugs (IMiDs) in multiple myeloma. Curr Cancer
Drug Targets. 17:846–857. 2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Scalzulli E, Grammatico S, Vozella F and
Petrucci MT: Proteasome inhibitors for the treatment of multiple
myeloma. Expert Opin Pharmacother. 19:375–386. 2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Usmani SZ, Heuck C, Mitchell A, Szymonifka
J, Nair B, Hoering A, Alsayed Y, Waheed S, Haider S, Restrepo A, et
al: Extramedullary disease portends poor prognosis in multiple
myeloma and is over-represented in high-risk disease even in the
era of novel agents. Haematologica. 97:1761–1767. 2012.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Katodritou E, Terpos E, Kastritis E,
Delimpasis S, Symeonidis AS, Repousis P, Kyrtsonis MC, Vadikolia C,
Michalis E, Polychronidou G, et al: Lack of survival improvement
with novel anti-myeloma agents for patients with multiple myeloma
and central nervous system involvement: The Greek myeloma study
group experience. Ann Hematol. 94:2033–2042. 2015.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Nieuwenhuizen L and Biesma DH: Central
nervous system myelomatosis: Review of the literature. Eur J
Haematol. 80:1–9. 2008.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Egan PA, Elder PT, Deighan WI, O'Connor
SJM and Alexander HD: Multiple myeloma with central nervous system
relapse. Haematologica. 105:1780–1790. 2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Dias ALMS, Higashi F, Peres ALM, Cury P,
Crusoé EQ and Hungria VTM: Multiple myeloma and central nervous
system involvement: Experience of a Brazilian center. Rev Bras
Hematol Hemoter. 40:30–36. 2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Varga G, Mikala G, Gopcsa L, Csukly Z,
Kollai S, Balázs G, Botond T, Wohner N, Horváth L, Szombath G, et
al: Multiple myeloma of the central nervous system: 13 cases and
review of the literature. J Oncol. 2018(3970169)2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Richardson PG, Zimmerman TM, Hofmeister
CC, Talpaz M, Chanan-Khan AA, Kaufman JL, Laubach JP, Chauhan D,
Jakubowiak AJ, Reich S, et al: Phase 1 study of marizomib in
relapsed or relapsed and refractory multiple myeloma: NPI-0052-101
Part 1. Blood. 127:2693–2700. 2016.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Millward M, Price T, Townsend A, Sweeney
C, Spencer A, Sukumaran S, Longenecker A, Lee L, Lay A, Sharma G,
et al: Phase 1 clinical trial of the novel proteasome inhibitor
marizomib with the histone deacetylase inhibitor vorinostat in
patients with melanoma, pancreatic and lung cancer based on in
vitro assessments of the combination. Invest New Drugs.
30:2303–2317. 2012.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Badros A, Singh Z, Dhakal B, Kwok Y,
MacLaren A, Richardson P, Trikha M and Hari P: Marizomib for
central nervous system-multiple myeloma. Br J Haetomal.
177:221–225. 2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Elhassadi E, Murphy M, Hacking D and
Farrell M: Durable treatment response of relapsing CNS plasmacytoma
using intrathecal chemotherapy, radiotherapy, and Daratumumab. Clin
Case Rep. 6:723–728. 2018.PubMed/NCBI View Article : Google Scholar
|
